Lawrence N. Shulman, MD

Lawrence N. Shulman, MD, Lawrence N. Shulman, MD, chief of staff, senior vice president for medical affairs, director, Center for Global Cancer Medicine, director, Department of Regional Strategy and Development, chief, Division of General Oncology, Dana-Farber Cancer Institute, discusses molecular testing.

Molecular testing for all types of cancer is more complex than previously thought

Physicians need to keep molecular testing guidelines current

There are 60-70 different EGFR mutations and each mutation has different significance for different therapies

Physicians learned at the 2013 Chemotherapy Foundation Symposium that patients with HER2 mutations in breast cancer will need different therapies than patients who have amplification or overexpression of HER2

Videos

Lawrence N. Shulman, MD, discusses molecular testing.

The Complexities of Molecular Testing

Lawrence N. Shulman, MD, chief of staff, senior vice president for medical affairs, director, Center for Global Cancer Medicine, director, Department of Regional Strategy and Development, chief, Division of General Oncology, Dana-Farber Cancer Institute, discusses the results of the CALGB 40101 trial.

The CALGB 40101 trial looked at patients who had 0-3 positive axillary nodes and 90% of the patients enrolled in the trial had node-negative disease

The trial compared standard chemotherapy (adjuvant cyclophosphamide (AC) and doxorubicin) versus paclitaxel. Patients received 6 cycles or 4 cycles of either treatment

The trial showed that 6 cycles of therapy was not superior to 4 cycles of therapy in any of the subgroups and that paclitaxel was not equivalent to AC

Lawrence N. Shulman, MD,discusses the results of the CALGB 40101 trial.

Lawrence N. Shulman, MD | Authors

Articles

The Complexities of Molecular Testing

An Overview of the CALGB 40101 Trial in Breast Cancer